Original Article
  

Risk Factors and Comorbidities of Recurrent Nasal Polyposis

Abstract

Chronic rhinosinusitis is divided into two groups, which are Chronic rhinosinusitis with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP). The rate of post-surgical recurrence in the CRSwNP is high, and predicting factors are unknown. This study aims to identify and evaluate risk factors associated with treatment-resistant and recurrent CRSwNP.
This cross-sectional study evaluates demographic data and atopic risk factors in patients with CRSwNP, including a high IgE level (≥100 U/mL), skin prick test (SPT) for aeroallergens, aspirin-exacerbated respiratory disease (AERD), and asthma prevalence. An oral aspirin challenge was performed to diagnose AERD. 191 patients with CRSwNP were enrolled, with 73 patients in the recurrent, and 118 patients in the non-recurrent group. The mean age of the patients in the recurrent group was 45.08±12.05. The mean age of the patients in the non-recurrent group was 42.89±11.73. 49. Asthma prevalence in recurrent- CRSwNP is significantly higher than non-recurrent CRSwNP Asthma severity in recurrent CRSwNP and AERD patients was significantly higher than in nonrecurrent CRSwNP and non-AERD patients. The level of IgE in the recurrent- CRSwNP is higher than non-recurrent CRSwNP. Positive SPT results for tree, weed, and mite allergens were higher in the non-recurrent- CRSwNP group compared to the recurrent CRSwNPgroup.
Asthma had a significantly higher difference in AERD compared to non-AERD. The level of IgE in AERD is higher than non-AERD.
Recurrent CRSwNP patients and AERD patients had Higher IgE levels. Asthma is more prevalent and more severe in both AERD and recurrent CRSwNP. However, a positive SPT result has been seen higher in non-recurrent CRSwNP.

1. Piromchai P, Kasemsiri P, Laohasiriwong S, Thanaviratananich S. Chronic rhinosinusitis and emerging treatment options. Int J Gen Med. 2013;6:453-64.
2. Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int. 2015;64(2):121-30.
3. Nabavi M, Arshi S, Bahrami A, Aryan Z, Bemanian MH, Esmaeilzadeh H, et al. Increased level of interleukin-13, but not interleukin-4 and interferon-γ in chronic rhinosinusitis with nasal polyps. Allergol Immunopathol (Madr). 2014;42(5):465-71.
4. Kwah JH, Peters AT. Nasal polyps and rhinosinusitis. Allergy Asthma Proc. 2019;40(6):380-4.
5. Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic Rhinosinusitis with Nasal Polyps and Asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133-41.
6. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, Brook I, Ashok Kumar K, Kramper M, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2 Suppl):S1-S39.
7. Fandino M, Macdonald KI, Lee J, Witterick IJ. The use of postoperative topical corticosteroids in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis. Am J Rhinol Allergy. 2013;27(5):e146-57.
8. Xu X, Reitsma S, Wang Y, Fokkens WJ. Highlights in the advances of chronic rhinosinusitis. Allergy. 2021;76(11):3349-58.
9. Akhtar S, Ikram M, Azam I, Dahri T. Factors associated with recurrent nasal polyps: a tertiary care experience. J Pak Med Assoc. 2010;60(2):102-4.
10. Bai J, Huang JH, Price CPE, Schauer JM, Suh LA, Harmon R, et al. Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2022;150(2):352-61 e7.
11. Chen S, Zhou A, Emmanuel B, Thomas K, Guiang H. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020;36(11):1897-911.
12. Esmaeilzedeh H, Esmaeilzadeh E, Faramarzi M, Nabavi M, Farhadi M. Salicylate Food Intolerance and Aspirin Hypersensitivity in Nasal Polyposis. Iran J Immunol. 2017;14(1):81-8.
13. Zhang N, Holtappels G, Gevaert P, Patou J, Dhaliwal B, Gould H, et al. Mucosal tissue polyclonal IgE is functional in response to allergen and SEB. Allergy. 2011;66(1):141-8.
14. Kaboodkhani R, Bolkheir A, Esmaeilzadeh H, Faramarzi M, Ashraf M, Hosseinialhashemi M, et al. Aspirin Exacerbated Respiratory Disease and Nasal Polyp Phenotyping. Iran J Pharm Res. 2021;20(4):21-8.
15. Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595-605.
16. Nabavi M, Esmaeilzadeh H, Arshi S, Bemanian MH, Fallahpour M, Bahrami A, et al. Aspirin hypersensitivity in patients with chronic rhinosinusitis and nasal polyposis: frequency and contributing factors. Am J Rhinol Allergy. 2014;28(3):239-43.
17. Luskin K, Thakrar H, White A. Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease. Immunol Allergy Clin North Am. 2020;40(2):329-43.
18. Chaaban MR, Walsh EM, Woodworth BA. Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy. 2013;27(6):473-8.
19. Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2017;5(4):1061-70.e3.
20. Esmaeilzadeh H, Nabavi M, Amirzargar AA, Aryan Z, Arshi S, Bemanian MH, et al. HLA-DRB and HLA-DQ Genetic Variability in Patients with Aspirin-Exacerbated Respiratory Disease. Am J Rhinol Allergy. 2015;29(3):e63-e9.
21. Ma C, Mehta NK, Nguyen SA, Gudis DA, Miglani A, Schlosser RJ. Demographic Variation in Chronic Rhinosinusitis by Subtype and Region: A Systematic Review. Am J Rhinol Allergy. 2022;36(3):367-77.
22. Sella GCP, Tamashiro E, Sella JA, Aragon DC, Mendonça TN, Arruda LKP, et al. Asthma Is the Dominant Factor for Recurrence in Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2020;8(1):302-9.
23. Wei B, Liu F, Zhang J, Liu Y, Du J, Liu S, et al. Multivariate analysis of inflammatory endotypes in recurrent nasal polyposis in a Chinese population. Rhinology. 2018;56(3):216-26.
24. Bochenek G, Szafraniec K, Kuschill-Dziurda J, Nizankowska-Mogilnicka E. Factors associated with asthma control in patients with aspirin-exacerbated respiratory disease. Respir Med. 2015;109(5):588-95.
25. Koskinen A, Salo R, Huhtala H, Myller J, Rautiainen M, Kääriäinen J, et al. Factors affecting revision rate of chronic rhinosinusitis. Laryngoscope Investig Otolaryngol. 2016;1(4):96-105.
26. Johns CB, Laidlaw TM. Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease. Am J Rhinol Allergy. 2014;28(4):287-9.
27. Buchheit KM, Dwyer DF, Ordovas-Montanes J, Katz HR, Lewis E, Vukovic M, et al. IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2020;145(6):1574-84.
28. Ashour ZA, Rabee H, El-Melegi HA, Attia MY, Sanad H. Evaluation of skin prick test sensitivity for 37 allergen extracts in atopic patients with nasal polyposis. Egypt J Intern Med. 2014;26(2):80-5.
29. Bavbek S, Yilmaz I, Celik G, Aydin O, Erkekol F, Orman A, et al. Prevalence of aspirin-exacerbated respiratory disease in patients with asthma in Turkey: a cross-sectional survey. Allergol Immunopathol (Madr). 2012;40(4):225-30.
Files
IssueVol 23 No 5 (2024) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijaai.v23i5.16746
Keywords
Aspirin-exacerbated respiratory disease Chronic rhinosinusitis with nasal polyps Recurrent nasal polyposis Skin prick test
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Esmaeilzadeh H, Shahhosseini B, Gholami MA, Nabavizadeh H, Alyasin S, Mortazavi N. Risk Factors and Comorbidities of Recurrent Nasal Polyposis. Iran J Allergy Asthma Immunol. 2024;23(5):502-513.